AU2014239583B2 - Recombinant RSV with silent mutations, vaccines, and methods related thereto - Google Patents

Recombinant RSV with silent mutations, vaccines, and methods related thereto Download PDF

Info

Publication number
AU2014239583B2
AU2014239583B2 AU2014239583A AU2014239583A AU2014239583B2 AU 2014239583 B2 AU2014239583 B2 AU 2014239583B2 AU 2014239583 A AU2014239583 A AU 2014239583A AU 2014239583 A AU2014239583 A AU 2014239583A AU 2014239583 B2 AU2014239583 B2 AU 2014239583B2
Authority
AU
Australia
Prior art keywords
rsv
codon
gene
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014239583A
Other languages
English (en)
Other versions
AU2014239583A1 (en
Inventor
Anne HOTARD
Elizabeth LITTAUER
Jia MENG
Martin L. MOORE
Christopher Stobart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Childrens Healthcare of Atlanta Inc
Original Assignee
Emory University
Childrens Healthcare of Atlanta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University, Childrens Healthcare of Atlanta Inc filed Critical Emory University
Publication of AU2014239583A1 publication Critical patent/AU2014239583A1/en
Application granted granted Critical
Publication of AU2014239583B2 publication Critical patent/AU2014239583B2/en
Priority to AU2020244533A priority Critical patent/AU2020244533B2/en
Priority to AU2023206177A priority patent/AU2023206177A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2014239583A 2013-03-14 2014-03-14 Recombinant RSV with silent mutations, vaccines, and methods related thereto Ceased AU2014239583B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020244533A AU2020244533B2 (en) 2013-03-14 2020-10-01 Recombinant RSV with silent mutations, vaccines, and methods related thereto
AU2023206177A AU2023206177A1 (en) 2013-03-14 2023-07-20 Recombinant RSV with silent mutations, vaccines, and methods related thereto

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361781228P 2013-03-14 2013-03-14
US61/781,228 2013-03-14
US201361890500P 2013-10-14 2013-10-14
US61/890,500 2013-10-14
PCT/US2014/027447 WO2014152534A1 (en) 2013-03-14 2014-03-14 Recombinant rsv with silent mutations, vaccines, and methods related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020244533A Division AU2020244533B2 (en) 2013-03-14 2020-10-01 Recombinant RSV with silent mutations, vaccines, and methods related thereto

Publications (2)

Publication Number Publication Date
AU2014239583A1 AU2014239583A1 (en) 2015-10-15
AU2014239583B2 true AU2014239583B2 (en) 2020-07-02

Family

ID=51581238

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014239583A Ceased AU2014239583B2 (en) 2013-03-14 2014-03-14 Recombinant RSV with silent mutations, vaccines, and methods related thereto
AU2020244533A Ceased AU2020244533B2 (en) 2013-03-14 2020-10-01 Recombinant RSV with silent mutations, vaccines, and methods related thereto
AU2023206177A Abandoned AU2023206177A1 (en) 2013-03-14 2023-07-20 Recombinant RSV with silent mutations, vaccines, and methods related thereto

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020244533A Ceased AU2020244533B2 (en) 2013-03-14 2020-10-01 Recombinant RSV with silent mutations, vaccines, and methods related thereto
AU2023206177A Abandoned AU2023206177A1 (en) 2013-03-14 2023-07-20 Recombinant RSV with silent mutations, vaccines, and methods related thereto

Country Status (8)

Country Link
US (4) US10232032B2 (enExample)
EP (2) EP3798310A1 (enExample)
JP (4) JP6506249B2 (enExample)
CN (2) CN113322264B (enExample)
AU (3) AU2014239583B2 (enExample)
ES (1) ES2854673T3 (enExample)
PL (1) PL2970981T3 (enExample)
WO (1) WO2014152534A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2854673T3 (es) 2013-03-14 2021-09-22 Univ Emory VSR recombinante con mutaciones silenciosas, vacunas y métodos relacionados con ello
EP3368547A4 (en) * 2015-10-29 2019-06-05 Emory University CHIMERIC RSV, IMMUNOGENIC COMPOSITIONS AND METHOD FOR USE THEREOF
KR20220041966A (ko) 2016-04-05 2022-04-01 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 용해성 융합-전 rsv f 단백질
WO2017207480A1 (en) * 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
WO2019162532A1 (en) 2018-02-26 2019-08-29 Stiftung Tierärztliche Hochschule Hannover (Tiho) Improved pneumovirus reverse genetics
JP2022513025A (ja) * 2018-11-13 2022-02-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前ｒｓｖ ｆタンパク質
EP3923983A4 (en) * 2019-02-11 2023-02-22 Emory University RSV AND HMPV CHIMERIC F-PROTEINS, IMMUNOGENIC COMPOSITIONS, AND METHODS OF USE
KR20240004448A (ko) * 2021-04-08 2024-01-11 코다제닉스 인코포레이티드 호흡기 세포융합 바이러스에 대한 면역 반응을 유도하는 방법
US12304929B2 (en) * 2021-04-12 2025-05-20 Sk Bioscience Co., Ltd. Recombinant RSV live vaccine strain and the preparing method thereof
US20240082385A1 (en) * 2022-05-27 2024-03-14 Meissa Vaccines, Inc. Rsv vaccines and methods of administering same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124238A1 (en) * 2013-02-08 2014-08-14 The United Of America, As Represented By The Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AT401526B (de) 1993-02-10 1996-09-25 Scheirer Winfried Reagenzlösung zur stabilisierung der lumineszenz bei der luciferasemessung
ATE257175T1 (de) 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
CA2230033C (en) 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US7846455B2 (en) * 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6923971B2 (en) 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
CN101012454B (zh) 1996-07-15 2011-11-16 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
WO2001089562A1 (en) 2000-05-25 2001-11-29 Medimmune, Inc. F-protein epitope-based vaccine for respiratory syncytial virus infection
ATE469170T1 (de) 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
EP1699919B1 (en) 2003-12-24 2017-01-11 De Staat der Nederlanden, Vertegenwoordigd Door de Minister Van Volksgezondheid, Welzijn en Sport A respiratory syncytial virus with a genomic deficiency complemented in trans
DK3312272T3 (da) 2004-10-08 2019-12-02 Us Gov Health & Human Services Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US8772256B2 (en) * 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
EP2139515B2 (en) 2007-03-30 2023-12-20 The Research Foundation of the State University of New York Attenuated viruses useful for vaccines
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
US9011876B2 (en) * 2008-11-05 2015-04-21 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus
DK2370099T3 (en) * 2008-12-09 2016-08-01 Novavax Inc Rsv f modified proteins and methods of their use
SG178026A1 (en) 2009-07-15 2012-03-29 Novartis Ag Rsv f protein compositions and methods for making same
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
BR112013029169B1 (pt) 2011-05-13 2021-09-28 Novartis Ag Polipeptídeo f pré-fusão do vírus sincicial respiratório (rsv), composição imunogênica e uso da mesma
US9492525B2 (en) 2011-07-06 2016-11-15 Nanobio Corporation Human respiratory syncytial virus vaccine
US8816081B2 (en) 2012-08-06 2014-08-26 Basf Se Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
AU2014243756B2 (en) 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
ES2854673T3 (es) * 2013-03-14 2021-09-22 Univ Emory VSR recombinante con mutaciones silenciosas, vacunas y métodos relacionados con ello
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
EP3368547A4 (en) 2015-10-29 2019-06-05 Emory University CHIMERIC RSV, IMMUNOGENIC COMPOSITIONS AND METHOD FOR USE THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124238A1 (en) * 2013-02-08 2014-08-14 The United Of America, As Represented By The Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

Also Published As

Publication number Publication date
AU2020244533A1 (en) 2020-10-29
HK1218428A1 (zh) 2017-02-17
CN105189756A (zh) 2015-12-23
US20160030549A1 (en) 2016-02-04
JP6506249B2 (ja) 2019-04-24
AU2023206177A1 (en) 2023-08-10
JP6956965B2 (ja) 2021-11-02
CN113322264B (zh) 2024-05-31
AU2020244533B2 (en) 2023-04-20
US20190224306A1 (en) 2019-07-25
US10792356B2 (en) 2020-10-06
EP2970981B1 (en) 2020-10-28
US20230302115A1 (en) 2023-09-28
WO2014152534A1 (en) 2014-09-25
US10232032B2 (en) 2019-03-19
AU2014239583A1 (en) 2015-10-15
ES2854673T3 (es) 2021-09-22
JP2023062157A (ja) 2023-05-02
JP2019115356A (ja) 2019-07-18
JP2016513471A (ja) 2016-05-16
EP3798310A1 (en) 2021-03-31
US12186386B2 (en) 2025-01-07
CN105189756B (zh) 2021-06-11
EP2970981A4 (en) 2017-02-22
EP2970981A1 (en) 2016-01-20
PL2970981T3 (pl) 2021-07-05
JP7239948B2 (ja) 2023-03-15
CA2906606A1 (en) 2014-09-25
US20210100893A1 (en) 2021-04-08
CN113322264A (zh) 2021-08-31
US11471524B2 (en) 2022-10-18
JP2022023054A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
US12186386B2 (en) Recombinant RSV with silent mutations, vaccines, and methods related thereto
US12257296B2 (en) Chimeric RSV, immunogenic compositions, and methods of use
US10626378B2 (en) Respiratory syncytial virus expression vectors
US20220125909A1 (en) Chimeric rsv and hmpv f proteins, immunogenic compositions, and methods of use
US20240082385A1 (en) Rsv vaccines and methods of administering same
CA2906606C (en) Recombinant rsv with silent mutations, vaccines, and methods related thereto
HK1218428B (zh) 具有沉默突变的重组rsv、其相关疫苗和方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired